Evoke Pharma (EVOK)
NASDAQ:EVOK
Holding EVOK?
Track your performance easily

Evoke Pharma (EVOK) Income Statement

461 Followers

Evoke Pharma Income Statement

Last quarter (Q3 2024), Evoke Pharma's total revenue was $2.65M, an increase of 69.83% from the same quarter last year. In Q3, Evoke Pharma's net income was $-1.31M. See Evoke Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 8.62M$ 5.18M$ 2.51M$ 1.62M$ 23.02K-
Cost of Revenue
$ 59.02K$ 201.88K$ 370.39K$ 328.12K$ 86.71K-
Gross Profit
$ 8.51M$ 4.98M$ 2.14M$ 1.29M$ -63.69K-
Operating Expense
$ 14.31M$ 12.41M$ 9.92M$ 9.77M$ 13.07M$ -7.15M
Operating Income
$ -5.90M$ -7.43M$ -7.79M$ -8.15M$ -13.05M$ -7.15M
Net Non Operating Interest Income Expense
$ -248.47K$ -361.40K$ -437.99K$ -491.44K$ -107.32K$ 28.80K
Other Income Expense
---$ -105.13K--
Pretax Income
$ -6.09M$ -7.79M$ -8.22M$ -7.88M$ -12.98M$ -7.13M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -6.15M$ -7.79M$ -8.22M$ -8.54M$ -13.15M$ -7.13M
Basic EPS
$ -4.51$ -2.33$ -2.62$ -3.24$ -6.24-
Diluted EPS
$ -4.51$ -2.33$ -2.62$ -3.24$ -6.24$ -3.84
Basic Average Shares
$ 6.86M$ 3.34M$ 3.14M$ 2.68M$ 2.12M$ 1.86M
Diluted Average Shares
$ 6.86M$ 3.34M$ 3.14M$ 2.68M$ 2.12M$ 1.86M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 14.52M$ 12.61M$ 10.29M$ 9.77M$ 13.07M$ -7.15M
Net Income From Continuing And Discontinued Operation
$ -6.15M$ -7.79M$ -8.22M$ -8.54M$ -13.15M$ -7.13M
Normalized Income
$ -5.36M$ -5.84M-$ -6.23M--
Interest Expense
------
EBIT
$ -5.55M$ -7.29M$ -7.72M$ -8.04M$ -13.04M$ -7.13M
EBITDA
$ -5.55M$ -7.29M$ -7.72M$ -8.04M$ -13.04M$ -7.13M
Currency in USD

Evoke Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis